Table of Contents

• Trial overview
• Rheumatoid arthritis study
• Idiopathic inflammatory myopathy extension study
• Outcomes and endpoints
• Study design terms
• What patients should know

Trial overview

The available trial data shows HYDROXYCHLOROQUINE used in a Phase 3 study for rheumatoid arthritis and listed as one of several drugs in another Phase 3 study for idiopathic inflammatory myopathy, including dermatomyositis and polymyositis.^[1][1]

These trials are not about the drug alone as a stand-alone topic. They are part of larger research studies that compare treatments, check response, and measure safety in specific patient groups.^[1][1]

Rheumatoid arthritis study

One completed trial was a randomized, placebo-controlled, double-blind, parallel group study in patients with moderately to severely active rheumatoid arthritis.^[1]

This means people were assigned by chance to different study groups, a placebo was used for comparison, and neither the participants nor the study team knew who received which treatment during the study.^[1]

The study enrolled 189 participants and tested the efficacy and safety of subcutaneous CT-P13, while HYDROXYCHLOROQUINE was one of the listed study drugs used in the trial setting.^[1]

The trial was completed.^[1]

Idiopathic inflammatory myopathy extension study

Another trial was an open-label extension study in people with idiopathic inflammatory myopathies, including dermatomyositis and polymyositis, who had already finished the treatment period of a qualifying parent study.^[1]

This study was authorised, was in Phase 3, and enrolled 182 participants.^[1]

Its brief goal was to evaluate the long-term safety of dazukibart in people with dermatomyositis or polymyositis, while the intervention list also included HYDROXYCHLOROQUINE among many other medicines used in the study context.^[1]

Outcomes and endpoints

The main result in the rheumatoid arthritis trial was the proportion of patients who reached ACR20 at Week 12.^[1]

ACR20 means at least a 20% improvement in arthritis signs and symptoms, so it is a simple way to measure whether treatment helped patients.^[1]

In the myopathy extension study, the primary outcomes focused on safety and monitoring, including TEAEs, SAEs, AESIs, lab test changes, ECG measurements, vital signs, lung function changes, and C-SSRS results.^[1]

TEAEs are treatment-emergent adverse events, SAEs are serious adverse events, and AESIs are adverse events of special interest.^[1]

The lung function measures included change from baseline in FVC and DLCO, and C-SSRS tracked suicidal thoughts and behavior at scheduled time points.^[1]

Study design terms

Open-label means that the people in the study and the study team know what treatment is being given.^[1]

Placebo-controlled means the trial used a non-active comparison treatment to help show whether the study treatment works better than no active treatment.^[1]

Parallel group means different groups were followed at the same time, rather than one group switching to another treatment later.^[1]

Extension study means a follow-up study after a parent trial, often used to collect longer-term data.^[1]

What patients should know

Based on the trial data, HYDROXYCHLOROQUINE appears as part of studies in two different disease areas: rheumatoid arthritis and idiopathic inflammatory myopathy.^[1][1]

The studies were in Phase 3, which is a later stage of clinical research that usually includes more participants and focuses on real treatment effects and safety monitoring.^[1][1]

The main questions were whether treatment helped patients, how safe it was, and how patients changed over time using standard outcome measures.^[1][1]